Novelos slides after lead drug fails Phase III lung cancer trial
This article was originally published in Scrip
Novelos Therapeutics' lead product, NOV-002, a proprietary formulation of oxidised glutathione, has failed to improve overall survival in its pivotal Phase III trial in advanced non-small cell lung cancer (NSCLC), sending the company's shares sliding by 81% to close at $0.32 on February 24th.
You may also be interested in...
The development of drugs to prevent cancer has lagged far behind the development of drugs, such as the statins, to prevent cardiovascular disease. But consideration of new, "personalised" clinical trial designs and an improved understanding of the biology of precancers, as well as new agents which target their molecular abnormalities, may make the field a more promising investment, says Malini Guha.
Janssen-Cilag's (Johnson & Johnson) injectable drug Xeplion (paliperidone palmitate) has been recommended for European approval by the CHMP for the treatment of schizophrenia.
The CHMP has recommended for European approval Pfizer's Xiapex (collagenase clostridium histolyticum) for the treatment of Dupuytren’s contracture, a potentially debilitating hand condition.